Ph 1 Study Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After PTCy
Phase 1 Study of Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After Post-transplantation Cyclophosphamide
This phase 1, single-center, open-label dose-escalation study will evaluate the safety, tolerability, and immune reconstitution effects of efineptakin alfa (rhIL-7-hyFc, NT-I7) administered after allogeneic hematopoietic cell transplantation (allo-HCT) in participants receiving post-transplantation cyclophosphamide (PTCy)-based graft-versus-host disease prophylaxis.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Maria Urdiales Kouba
- Número de teléfono: 813-745-1218
- Correo electrónico: Maria.UrdialesKouba@moffitt.org
Ubicaciones de estudio
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt Cancer Center
-
Sub-Investigador:
- Melissa Alsina, MD
-
Sub-Investigador:
- Lia Perez, MD
-
Sub-Investigador:
- Doris Hansen, MD
-
Sub-Investigador:
- Rawan Faramand, MD
-
Sub-Investigador:
- Hien Liu, MD
-
Sub-Investigador:
- Omar Castaneda Puglianini, MD
-
Sub-Investigador:
- Michael Jain, MD
-
Sub-Investigador:
- Asmita Mishra, MD
-
Sub-Investigador:
- Taiga Nishihori, MD
-
Sub-Investigador:
- Nelli Bejanyan, MD
-
Sub-Investigador:
- Farhad Khimani, MD
-
Sub-Investigador:
- Aleksandr Lazaryan, MD
-
Sub-Investigador:
- Fabiana Perna, MD
-
Sub-Investigador:
- Joseph Pidala, MD
-
Sub-Investigador:
- Reshma Ramlal, MD
-
Investigador principal:
- Sayeef Mirza, MD
-
Sub-Investigador:
- Alaa Ali, MD
-
Sub-Investigador:
- Deepakbabu Chellapanian, MD
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- First allogeneic HCT with peripheral blood as the only graft source used for allo HCT.
- Diagnosis of hematologic malignancy eligible for allo-HCT.
- Only patients with plan for post-transplant cyclophosphamide based GVHD prophylaxis are eligible.
- Eligible donors include matched-related, matched-unrelated, mismatched unrelated, and HLA-haploidentical relatives with a shared HLA haplotype with the patient, determined by high-resolution DNA typing at HLA-A, -B, -C, and -DRB1 loci per standardof care practice as documented in the medical record.
- Granulocyte-colony stimulating factor (G-CSF)-mobilized donor peripheral blood hematopoietic cells were targeted to a CD34+ cell dose of 5 × 106/kg with a minimum accepted dose of 2 × 106 cells per kg and a maximum dose of 10 × 106 cells per kg.
- Patient age ≥18 years at time of consent.
- Karnofsky performance status of ≥80% for the myeloablative and ≥60% for the nonmyeloablative (NMA) regimens.
- Patients with documented engraftment but require granulocyte-colony stimulating factor (G-CSF) to treat myelosuppression induced by drugs used to treat or prevent infection are eligible with G-CSF washout at least 14 days prior to Efineptakin Alfa.
- Participants must have adequate organ and marrow function
- Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Absence of dyspnea or hypoxia (< 90% of saturation by pulse oximetry on room air).
- The effects of rh-IL-7 on the developing human fetus are unknown. For this reason and because immunomodulatory agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men treated or enrolled on this protocol must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for an additional four months after completion of the last study drug administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Progressive or advanced hematological malignancy.
- Patients with acute GVHD requiring systemic immunosuppression within the first 30 days (to avoid confounding lymphopenia from GVHD and steroid therapy). (Patients receiving GVHD prophylaxis will be allowed on this study).
- Patients who fail to achieve engraftment by day 30 post-HCT (for safety concerns, and due to major interventions including second HCT done in the setting of engraftment failure).
- History of Epstein-Barr virus (EBV) associated lymphoproliferation.
- Active uncontrolled viral, bacterial or fungal infection.
- History of autoimmune disease.
- Receiving systemic corticosteroid therapy (budesonide is allowed).
- Uncontrolled hypertension as defined by Systolic BP ≥ 160 mmHg or Diastolic BP ≥ 100 mmHg, confirmed by repeat measurement after appropriate rest.
- Corrected QT (QTcF) prolongation (QTcF > 470 ms) or prior history of significant arrhythmia or electrocardiogram (ECG) abnormalities.
- Presence of donor-specific antibodies.
- Inability or unwillingness to provide signed informed consent or comply with the study requirements.
- Participants who have not recovered from non-hematologic adverse events (AEs) due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1), with the exception of alopecia.
- Participants who are receiving any other investigational agents.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to rh-IL7 or other agents in the conditioning or GVHD prophylaxis regimen.
- Participants receiving any medications or substances that are prohibited while on study (see section 6.7.). As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
- Participants with psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant or nursing women will be excluded from this study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Efineptakin Alfa (rhIL-7-hyFc)
Participants will receive a single intramuscular dose of efineptakin alfa (NT-I7, rhIL-7-hyFc) on Day +60 after allogeneic hematopoietic cell transplantation. Dose assignment will follow a phase 1 dose-escalation design with dose levels of 240 μg/kg, 480 μg/kg, and 720 μg/kg. |
Single intramuscular administration on Day +60 after allo-HCT. Dose escalation includes 240 μg/kg, 480 μg/kg, and 720 μg/kg. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recommended phase II dose (RP2D)
Periodo de tiempo: Up to 90 days
|
Determine the recommended phase 2 dose (RP2D) of efineptakin alfa. |
Up to 90 days
|
|
Absolute Lymphocyte Count Recovery
Periodo de tiempo: Up to 90 days
|
Proportion of participants achieving an absolute lymphocyte count (ALC) ≥1,000 cells/mm³ at Day +90 following transplantation. |
Up to 90 days
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Occurrence of infections
Periodo de tiempo: Up to 100 days
|
Defined as developing (or experiencing re-activation) of a viral, bacterial, or fungal infection by Day +100. |
Up to 100 days
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Sayeef Mirza, MD, Moffitt Cancer Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- MCC-23978
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .